Market Place
Sourcing Support
Lilly Completes Acquisition of Sigilon Therapeutics
14 Aug 2023 //
PR NEWSWIRE
Lilly’s yes-no-yes journey to acquiring Sigilon
13 Jul 2023 //
FIERCE BIOTECH
Lilly buys diabetes cell therapy partner Sigilon for $35M
30 Jun 2023 //
FIERCE BIOTECH
Lilly to Acquire Diabetes Cell Therapy Company Sigilon Therapeutics
29 Jun 2023 //
CONTRACT PHARMA
Sigilon Announces Reverse Stock Split of Common Stock
22 May 2023 //
GLOBENEWSWIRE
Sigilon Therapeutics Reports1Q 2023 FYR and Business Highlights
09 May 2023 //
GLOBENEWSWIRE
Sigilon Therapeutics to Present at the Needham Virtual Healthcare Conference
18 Apr 2023 //
GLOBENEWSWIRE
Sigilon focuses on type 1 diabetes, reduces spend on MPS-1 after letting CMO go
15 Mar 2023 //
ENDPTS
Sigilon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
14 Mar 2023 //
GLOBENEWSWIRE
Sigilon Therapeutics Reports 3Q 2022 Financial Results and Business Highlights
10 Nov 2022 //
GLOBENEWSWIRE
Sigilon Therapeutics Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
GLOBENEWSWIRE
Sigilon Therapeutics Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Sigilon Therapeutics to Present at the Needham Healthcare Conference
07 Apr 2022 //
GLOBENEWSWIRE
Sigilon Tx Reports Q4 and Full Year 2021 Financial Results
14 Mar 2022 //
GLOBENEWSWIRE
Sigilon Tx to Present at the Barclays Global Healthcare Conference
08 Mar 2022 //
GLOBENEWSWIRE
Sigilon Tx Appoints Sarah Yuan, Ph.D., as Chief Technical Operations Officer
22 Feb 2022 //
BIOSPACE
Sigilon to Present Preclinical Data at the 18th Annual WORLDSymposium
31 Jan 2022 //
BIOSPACE
Sigilon Therapeutics Announces Strategic Reprioritization
13 Dec 2021 //
GLOBENEWSWIRE
Sigilon Therapeutics Announces Update on SIG-001 Phase 1/2 Study in Hemophilia A
29 Nov 2021 //
GLOBENEWSWIRE
Sigilon Therapeutics to Participate in the Jefferies Conference
09 Nov 2021 //
GLOBENEWSWIRE
MHRA accepts CTA of Sigilon Therapeutics for SIG-005 in MPS-1
09 Sep 2021 //
GLOBENEWSWIRE
Sigilon Preclinical Data International Symposium on MPS and Related Diseases
23 Jul 2021 //
GLOBENEWSWIRE
Sigilon Preclinical Data International Symposium on MPS and Related Diseases
23 Jul 2021 //
GLOBENEWSWIRE
Sigilon Preclinical Data International Symposium on MPS and Related Diseases
23 Jul 2021 //
GLOBENEWSWIRE
FDA puts Sigilon’s hemophilia cell therapy trial on hold
09 Jul 2021 //
FIERCEBIOTECH
Sigilon Therapeutics Announces Clinical Hold on SIG-001 Ph 1/2 Study
09 Jul 2021 //
GLOBENEWSWIRE
Sigilon Reports Q4 and Full Year 2020 Financial Results and Business Highlights
18 Mar 2021 //
GLOBENEWSWIRE
Sigilon Therapeutics Receives Orphan Drug Designation for SIG-005
17 Dec 2020 //
GLOBENEWSWIRE
Sigilon Receives Orphan Designation for SIG-005 forMucopolysaccharidosis Type I
17 Dec 2020 //
GLOBENEWSWIRE
Chronic disease biotech Sigilon Therapeutics files for a $100 million IPO
13 Nov 2020 //
RENAISSANCECAPITAL
Moleculin Signs Agreement with UTMB to Test WP1122 on a Range of Viruses
17 Mar 2020 //
PR NEWSWIRE
Sigilon Receives Orphan Drug Designation for SIG-001 for the Treatment of Hem A
27 Aug 2019 //
BUSINESSWIRE
Wotton named CEO of cell, gene therapy startup Obsidian
18 Apr 2019 //
FIERCE BIOTECH
Novo Nordisk steps up interest in diabetes stem cell therapies
17 May 2018 //
FIERCE BIOTECH
